Saltar al contenido
Merck

C2538

Carboplatin

DNA cross-linking agent, powder

Sinónimos:

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Acerca de este artículo

Fórmula lineal:
[C4H6(CO2)2]Pt(NH3)2
Número CAS:
41575-94-4
Peso molecular:
371.25
NACRES:
NA.77
PubChem Substance ID:
24278303
UNSPSC Code:
12352200
EC Number:
255-446-0
MDL number:
MFCD00070464

Documentos clave

Ver Toda la documentación
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Carboplatin,

InChI key

OLESAACUTLOWQZ-UHFFFAOYSA-L

InChI

1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2

SMILES string

N.N.O=C1O[Pt]OC(=O)C12CCC2

form

powder

antibiotic activity spectrum

neoplastics

originator

Bristol-Myers Squibb

Quality Level

100

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Application

Carboplatin has been used:
  • in chemotherapy-induced thrombocytopenia mouse model and treatment
  • to induce cell death in a large subset of colorectal cancer cells
  • in the evaluation of cell proliferation and chemosensitivity
  • as a positive control for suppressed cell growth

Biochem/physiol Actions

Carboplatin is a platinum-based antineoplastic drug that damages DNA by forming intrastrand cross-links with neighboring guanine residues. Tumors acquire resistance to these drugs through the loss of DNA-mismatch repair (MMR) activity and the resultant decrease in the induction of programmed cell death.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Carboplatin is used to treat testicular, ovarian and breast cancer.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Muta. 1B - Repr. 1B - Resp. Sens. 1 - Skin Sens. 1

Clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
MKCZ0527
MKCW1333
MKCT7823
MKCR3593
MKCR8746

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Osteoblasts support megakaryopoiesis through production of interleukin 9
Xiao M, et al.
Blood, blood-b2016 (2017)
Joel Shapiro et al.
Annals of surgery, 258(5), 678-688 (2013-10-08)
To gain insight into the exact location of residual esophageal cancer in the esophageal wall and regional lymph nodes after neoadjuvant chemoradiotherapy (nCRT) and to determine the pattern of regression. Data from the recently published chemoradiotherapy for oesophageal cancer followed
Furqan Shaikh et al.
Pediatric blood & cancer, 60(4), 587-592 (2012-09-15)
While cisplatin is considered superior to carboplatin for the treatment of malignant germ cell tumors (MGCTs) in adults, pediatric oncology collaborative groups still remain concerned about the late effects of cisplatin in children. We performed a literature search to identify
Michael D Nyquist et al.
Cell reports, 31(8), 107669-107669 (2020-05-28)
Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with neuroendocrine (NE) differentiation. Therapeutic strategies that address these aggressive variant
Mun Sem Liew et al.
BJU international, 112 Suppl 2, 74-82 (2013-10-30)
To review time-trends in the use of perioperative chemotherapy and its impact on oncological outcomes in patients with bladder urothelial cancer (UC) at a single tertiary institution. Using electronic and paper medical records, 89 patients were identified who underwent radical
Ver todos los artículos relacionados

Contenido relacionado

Product Information Sheet - C2538

Product Information Sheet

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico